US Patent Application 20120107391 - THERAPY OF PLATINUM-RESISTANT CANCER
InventorAssigneeUS Classes424/450, Liposomes424/138.1, Binds expression product or fragment thereof of cancer-related gene (e.g., oncogene, proto-oncogene, etc.)424/133.1Structurally-modified antibody, immunoglobulin, or fragment thereof (e.g., chimeric, humanized, CDR-grafted, mutated, etc.)International ClassesA61K 39/395A61P 35/00 A61K 9/127 Abstract textThe present invention concerns a method for treating platinum-resistant, ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma with the combination of a HER2 antibody that effectively inhibits HER dimerization as well as gemcitabine. |
| ||||||||||||||
